Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Imidacloprid/moxidectin combination against naturally acquired canine scabies
Scabies (sarcoptic mange) is a common and highly pruritic disease in dogs which often is misdiagnosed as an allergy. Some therapies are very efficious but not licensed in dogs. Is the licensed and very comfortable therapy with an imidacloprid plus moxidectin spot-on formulation both licensed and efficious?

The study was undertaken to evaluate and compare the efficacy of an imidacloprid (10% w/v) / moxidectin (2.5% w/v) combination (Advocate® Bayer HealthCare, Animal Health) with that of selamectin for the treatment of Sarcoptes scabiei on dogs.

Thirty naturally infested dogs, of which one was later withdrawn because of distemper, were allocated to two equal groups and individually housed.

The dogs in each group were treated twice, four weeks apart, with either the combination product (0.1 mL/kg body weight) or with selamectin (0.05 mL/kg body weight) administered topically. Skin scrapings were made every 14 days over a period of 50 to 64 days after the first treatment to quantify mite numbers.

Clinical signs and the extent of sarcoptic lesions were assessed on each dog when skin scrapings were made.

Efficacy was based on the presence or absence of mites, supported by clinical signs associated with canine sarcoptic mange. From Day 22 and onwards no Sarcoptes mites were found in the skin scrapings of any of the treated dogs.

Treatment with the imidacloprid/moxidectin formulation or with selamectin was highly effective against Sarcoptes scabiei and resulted in an almost complete resolution of clinical signs within 50 to 64 days after the initial treatment.


Source: LJ FOURIE, J. HEINE, IG HORAK (2006): The efficacy of an imidacloprid/moxidectin combination against naturally acquired Sarcoptes scabiei infestations on dogs. In: Australian Veterinary Journal 84 (1-2), 17–21.


Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Wound bio-burden and prevalence of multi-drug resistant bacteria in open woundsmembers
This retrospective multicentre study describes the bacterial bio-burden of open-treated wounds and make comparisons with bite wounds. Are there important differences and does perioperative antibiotic therapy have to be reevaluated?

  • Concurrent perioperative use of marbofloxacin and cimicoxib or carprofenmembers
  • Topical hyaluronic acid and the corneal wound healing members
  • Moraxella phenylpyruvica infection leading to severe heart problems in an old dogmembers
  • Propofol versus propofol-alfentanil admixture for sedation in dogsmembers
  • Second-Generation NT-proBNP Measurements in Catsmembers
  • Cobalamin and Methylmalonic Acid Concentrations in Hyperthyroid Cats Before and After Therapymembers
  • Preoperative Differential Diagnosis of Canine Adrenal Tumors members
  • Atopic dermatitis and the intestinal microbiotamembers
  • Congenital portosystemic shunts involving the left colic vein members
  • Immunochromatographic test for feline AB system blood typingmembers
  • Open-angle glaucoma in the PBGVmembers
  • Sucralfate and the Relative Bioavailability of Enrofloxacin and Ciprofloxacin members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved